BSBree Shi

Bree Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bree Shi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design and Reporting Quality of Noninferiority Trials in Kidney Transplantation

    by Bree Shi, Jonathan M. Bleasel, Tracey Ying, Steven J. Chadban

    Key Points: Many kidney transplant noninferiority trials used unjustified or overly generous margins, risking adoption of inferior therapies. Inadequate analyses, poor missing data handling, and weak Consolidated Standards of Reporting Trials (CONSORT) adherence limit trial interpretation. Stronger noninferiority trial design and reporting are needed to improve evidence quality in kidney transplantation. Background: Noninferiority trials are essential in kidney transplantation, where established standard-of-care treatments make placebo-controlled designs infeasible, and their use is increasing. We aimed to assess the design and reporting quality of noninferiority trials in kidney transplantation, specifically assessing adherence to existing guidelines. Methods: We searched medical literature analysis and retrieval system online, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled noninferiority trials in kidney transplantation published up to February 2025. Two investigators reviewed and extracted data. Study quality was assessed regarding design and reporting quality using key noninferiority design criteria and the Consolidated Standards of Reporting Trials 2012 extension, respectively. Results: We identified 43 unique trials: 36 (84%) compared a novel immunosuppressive regimen to standard of care and 26 (60%) were industry sponsored. The noninferiority margin (the worst-case loss in efficacy considered clinically acceptable) was not justified in 28 (65%) studies and poorly justified in seven (16%). Of 32 studies with a categorical primary outcome, 30 (94%) assessed absolute risk reduction rather than relative risk. Most studies had high withdrawal and dropout rates, yet 33 (77%) did not specify methods for handling missing data. Intention-to-treat analysis alone was used to determine primary efficacy in 24 (56%) studies. Twelve studies (28%) provided an incorrect conclusion, most claiming equivalence when noninferiority had not been adequately demonstrated. Both design and reporting quality have improved over time ( P = 0.02, P = 0.002, respectively). No association was evident between design or reporting quality and journal impact factor or sponsor type. Conclusions: We found major deficiencies in the design, conduct, and reporting of noninferiority trials in kidney transplantation.


  • Open Access

    Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients

    by Griffith B. Perkins, Matthew J. Tunbridge, Cheng Sheng Chai, Christopher M. Hope, Arthur Eng Lip Yeow, Tania Salehi, Julian Singer, Bree Shi, Makutiro G. Masavuli, Zelalem Addis Mekonnen, et al.

    Key Points: Mechanistic target of rapamycin (mTOR) inhibitor–based immunosuppression was associated with an improved T-cell response to vaccination in kidney transplant recipients. Mice treated with an mTOR inhibitor exhibited improved T-cell responses to booster vaccination. Switching low and nonresponder kidney transplant recipients to an mTOR inhibitor did not improve T-cell response to a booster vaccination. Background: Failure to develop protective immunity in response to vaccination is common among kidney transplant recipients, rendering them susceptible to severe infection. Novel strategies are required. Here, we investigated the potential of mechanistic target of rapamycin (mTOR) inhibitors to improve vaccine responses. Methods: Humoral and cellular responses to primary coronavirus disease 2019 (COVID-19) vaccination (ChAdOx1 or BNT162b2) were assessed for kidney transplant recipients receiving mTOR inhibitor–based (mTOR inhibitor, mycophenolate, prednisolone, n =15) and standard-of-care (tacrolimus, mycophenolate, prednisolone, n =40) immunosuppression, and healthy cohabitants ( n =71), in a prospective observational study. Findings were validated and mechanisms explored in mice. Low/nonresponding kidney transplant recipients receiving standard-of-care immunosuppression ( N =54) were then randomized 1:1 to switch from mycophenolate to sirolimus or remain on standard of care for 4 weeks before receiving COVID-19 booster vaccination. Augmentation of immunity to COVID-19 was assessed as the primary outcome measure. Results: A 12-fold greater IFN γ T-cell response to primary vaccination was observed in kidney transplant recipients receiving mTOR inhibitor–based versus standard-of-care immunosuppression (520 versus 43 spot-forming units/10 6 cells, P < 0.001). A greater frequency of functional memory T cells in the mTOR inhibitor group was observed for both the CD4 + (0.20% versus 0.05%, P < 0.001) and CD8 + (0.35% versus 0.07%, P = 0.006) compartments by flow cytometry, and kidney transplant recipients receiving mTOR inhibitor–based immunosuppression produced greater frequencies of severe acute respiratory syndrome coronavirus 2–specific CD4 + T cells than healthy cohabitants (1.17% versus 0.48%, P = 0.03). In mice, sirolimus treatment enhanced both recall and de novo T-cell responses to homologous and Omicron-specific booster vaccines. Switch from mycophenolate to sirolimus was well tolerated; however, no significant difference was observed in the proportion of kidney transplant recipients in the intervention and control arms that achieved protective virus neutralization (10/25 [40%] versus 9/21 [43%], respectively, P = 0.85) nor in T-cell response to vaccination ( P = 0.89). Conclusions: mTOR inhibition was associated with improved T-cell memory formation in kidney transplant recipients; however, this effect was not reproduced by a short-term mycophenolate to sirolimus switch strategy. Clinical Trial registry name and registration number: Australian New Zealand Clinical Trials Registry, ACTRN12621001412820.